EUVIMEDEUVIMED entdecken
Netzwerk-MetaanalyseVergleichsstudieÜbersichtsarbeit

Comparative effectiveness of continuous positive airway pressure and glucagon‐like peptide‐1 receptor agonists in obstructive sleep apnea: A network meta‐analysis of randomised trials

Gaspar R Chiappa iD, Paula C N Santos, Deivyd Vieira Silva Cavalcante, Alberto Souza Sá Filho iD, Natalia Prado, Katia Marques Lombardo, Pedro Sanchez Sequero, Antonio M Esquinas iD

Diabetes, Obesity and Metabolism · 2026-05 · 28 (5) · 3557-3567

DOI: 10.1111/dom.70572 ↗

Kurz gefasst

Netzwerk-Metaanalyse in der Zeitschrift Diabetes, Obesity and Metabolism, online erschienen am 23.02.2026. Verfasst von Gaspar R Chiappa und 7 weiteren Autor:innen. Beteiligte Einrichtung: Graduate Program in Human Movement and Rehabilitation, Evangelical University of Goiás, Anápolis, Brazil. Hauptthemen laut MEDLINE: Sleep Apnea, Obstructive, Continuous Positive Airway Pressure, Glucagon-Like Peptide-1 Receptor Agonists. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 37 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

To compare the effects of continuous positive airway pressure (CPAP), glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs), their combination, and no active intervention on respiratory, sleepiness, and metabolic outcomes in adults with obstructive sleep apnea (OSA). We searched PubMed, Embase, and CENTRAL through August 2025 for randomised trials of CPAP, exenatide, liraglutide, tirzepatide, or their combinations. The primary endpoint was apnea–hypopnea index (AHI). Secondary endpoints were Epworth Sleepiness Scale (ESS), body mass index (BMI), systolic and diastolic blood pressure (SBP, DBP), fasting glucose, and glycated haemoglobin (HbA1c). Random‐effects network meta‐analyses estimated mean differences (MDs) with 95% confidence intervals (CIs). Treatments were ranked using SUCRA, and certainty of evidence was assessed with GRADE. Thirty‐four trials including 3964 participants were eligible. CPAP produced the largest reduction in AHI versus no active intervention (MD −22.17 events/h; 95% CI −38.01 to −6.33) and improved ESS (MD −2.75; 95% CI −3.71 to −1.79). Liraglutide reduced BMI (MD −1.60 kg/m 2 ; 95% CI −2.04 to −1.16) and HbA1c (MD −0.19%; 95% CI −0.25 to −0.13), whereas CPAP showed no meaningful metabolic effect. Liraglutide plus CPAP achieved the greatest BMI reduction (MD −2.00 kg/m 2 ; 95% CI −3.49 to −0.51). No intervention significantly changed SBP, DBP, or fasting glucose. According to GRADE, certainty of evidence was moderate for CPAP effects on respiratory and sleepiness outcomes and for GLP‐1 receptor agonists on BMI and HbA1c, and low for blood pressure and fasting glucose. CPAP is the most effective therapy for respiratory control, while GLP‐1 receptor agonists primarily improve weight and glycaemic indices, supporting an integrated airway–metabolic approach to OSA management.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Sleep Apnea, ObstructiveContinuous Positive Airway PressureGlucagon-Like Peptide-1 Receptor AgonistsHumansRandomized Controlled Trials as TopicTirzepatideLiraglutideExenatideTreatment OutcomeGlycated HemoglobinHypoglycemic Agents

Stichwörter der Autor:innen

GLP‐1 receptor agonistscardiometabolic outcomescontinuous positive airway pressurenetwork meta‐analysisobstructive sleep apnea

Substanzen

Glucagon-Like Peptide-1 Receptor AgonistsTirzepatideLiraglutideExenatideGlycated HemoglobinHypoglycemic Agents

Autor:innen und Institutionen

  • Graduate Program in Human Movement and Rehabilitation, Evangelical University of Goiás, Anápolis, Brazil.
  • Faculty of Health Sciences, Universidad Autónoma de Chile, Santiago, Chile.
  • College of Biomedical and Translational Sciences, University of North Texas Health, Fort Worth, Texas, USA.
  • Faculdade Multivix de Cachoeiro de Itapemirim, Cachoeiro de Itapemirim, Brazil.
  • Biomechanics Laboratory, State University of Santa Catarina, UDESC, Florianópolis, Brazil.
  • Department of Endocrinology, Metabolism and Nutrition, Hospital Morales Meseguer, Murcia, Spain.

ORCID-Profile: Gaspar R Chiappa, Alberto Souza Sá Filho, Antonio M Esquinas

Zitieren

APA

Chiappa, G. R., Santos, P. C. N., Cavalcante, D. V. S., Sá Filho, A. S., Prado, N., Lombardo, K. M., Sequero, P. S., & Esquinas, A. M. (2026). Comparative effectiveness of continuous positive airway pressure and glucagon‐like peptide‐1 receptor agonists in obstructive sleep apnea: A network meta‐analysis of randomised trials. Diabetes, Obesity and Metabolism, 28(5), 3557-3567. https://doi.org/10.1111/dom.70572

Vancouver

Chiappa GR, Santos PCN, Cavalcante DVS, Sá Filho AS, Prado N, Lombardo KM, et al. Comparative effectiveness of continuous positive airway pressure and glucagon‐like peptide‐1 receptor agonists in obstructive sleep apnea: A network meta‐analysis of randomised trials. Diabetes, Obesity and Metabolism. 2026;28(5):3557-3567. doi:10.1111/dom.70572

BibTeX
@article{Chiappa2026,
  author = {Chiappa, Gaspar R and Santos, Paula C N and Cavalcante, Deivyd Vieira Silva and Sá Filho, Alberto Souza and Prado, Natalia and Lombardo, Katia Marques and Sequero, Pedro Sanchez and Esquinas, Antonio M},
  title = {Comparative effectiveness of continuous positive airway pressure and glucagon‐like peptide‐1 receptor agonists in obstructive sleep apnea: A network meta‐analysis of randomised trials},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2026},
  volume = {28},
  number = {5},
  pages = {3557--3567},
  doi = {10.1111/dom.70572}
}
Kostenlos starten →